Andrea Wang-Gillam, MD, PhD of Washington University School of Medicine @WUSTLmed answers if the phase I study of defactinib combined with pembrolizumab and gemcitabine in patients with advanced cancer can be expanded. Presented at this year’s AACR Annual Meeting.
Andrea Wang-Gillam, MD on Phase I Study of Defactinib: Can We Expand This Study? #AACR #AACR20 @WUSTLmed
By Editor